IPHA - Innate Pharma SA

QQQ $ 431.01 $ 6.55 (1.54 %)

DIA $ 382.27 $ 1.39 (0.36 %)

SPY $ 508.26 $ 4.77 (0.95 %)

TLT $ 88.26 $ 0.46 (0.52 %)

GLD $ 216.60 $ 0.70 (0.32 %)

Previous Close

$ 2.46

Open

$ 2.27

Bid

$ 2.26 x 400

Ask

$ 2.48 x 400

Day's Range

$ 2.27 - $ 2.27

52 Week Range

$ 1.81 - $ 3.57

Volume

6,799

Average Volume

Market Cap

197.92M

Beta (5Y Monthly)

$ 1.36

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Innate Pharma Advances Sanofi-Developed NK...
04/15/2024 05:47:42

HC Wainwright & Co. Reiterates Buy on Inna...
04/11/2024 11:36:22

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $11.5...

Innate Pharma Presents Preclinical Efficac...
04/10/2024 06:55:11

IPH45 is a novel and differentiated exatecan-Antibody Drug Conjugate targeting Nectin-4 In PDX models of urothelial tumors, ...

Innate Pharma Says It Filed Its 2023 Unive...
04/05/2024 09:15:02

12-health-care-stocks-moving-in-wednesdays-after-market-session

12 Health Care Stocks Moving In Wednesday'...
04/03/2024 20:31:20

12-health-care-stocks-moving-in-mondays-pre-market-session

12 Health Care Stocks Moving In Monday's P...
04/01/2024 12:08:05

HC Wainwright & Co. Reiterates Buy on Inna...
03/22/2024 10:26:57

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $11.5...

Earnings Scheduled For March 21, 2024
03/21/2024 10:15:14

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per s...

Innate Pharma FY EPS $(0.10) Up From $(0.7...
03/21/2024 06:07:27

Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.10) per share. This is a 87.2 percent increase over losses of $(0....

12-health-care-stocks-moving-in-mondays-after-market-session

12 Health Care Stocks Moving In Monday's A...
03/11/2024 21:34:44

Innate Pharma Announces That It Will Prese...
03/06/2024 08:01:07

IPH45 abstract selected for oral presentation at AACR Annual Meeting 2024 Preclinical data support further development of IP...

$innate-pharmas-first-patient-dosed-in-phase-12-study-of-iph6501-in-relapsed-refractory-b-cell-non-hodgkins-lymphoma$

Innate Pharma's First Patient Dosed In Pha...
03/06/2024 07:59:05

Phase 1/2 study is evaluating IPH6501, a first-in-class CD20-targeting tetraspecific natural killer cell engager, from ANKET® p...

12-health-care-stocks-moving-in-tuesdays-pre-market-session

12 Health Care Stocks Moving In Tuesday's ...
02/06/2024 13:06:31

Innate Pharma Announces FDA's Removal Of P...
01/04/2024 07:23:32

FDA lifts partial clinical hold on lacutamab clinical program Fatal case related to disease progression and unrelated to the...

Innate Pharma Filed For Stock Shelf Of Up ...
12/20/2023 21:51:52

-F-3

Sanofi To Exercise Option To License A New...
12/19/2023 07:11:17

Sanofi to exercise one option to license a new ANKET® program from Innate; After a research collaboration period, Sanofi will...

Innate Pharma CEO Mondher Mahjoubi To Depa...
12/18/2023 07:10:22

Current CEO Mondher Mahjoubi to leave Innate Pharma to pursue an opportunity at a large pharmaceutical company Current Chair...

Reported On Sunday, Innate Pharma To Prese...
12/11/2023 08:21:22

Results confirm promising clinical activity, durable responses and favorable safety of lacutamab in heavily pretreated post-m...

Innate Pharma Shares Efficacy And Safety P...
12/11/2023 08:19:08

SAR443579/IPH6101, ANKET® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a jo...

Innate Pharma Announces Virtual Key Opinio...
11/27/2023 06:25:34

The event will highlight positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with ...